New partnership increases radiology's presence within the FDA's Network of Experts

The Radiological Society of North America is joining the U.S. Food and Drug Administration’s Network of Experts. 

RSNA made the announcement on Tuesday, April 18, indicating enthusiasm for the opportunity to share the renowned society’s expertise. The Network of Experts is a vetted group consisting of more than 100 organizations and their respective scientists, clinicians and engineers who provide guidance and expertise to the FDA when requested. 

RSNA’s involvement in the program will come by way of its Government Relations Committee, which will refer members of its network to the FDA when their expertise is needed. RSNA will be available to consult with the FDA on various matters relative to radiologic science, medical devices and pharmaceuticals under the Center for Devices and Radiological Health and the Center for Drug Evaluation and Research (CDER). 

“By joining the FDA Network of Experts, RSNA leaders in technology and innovation will have the opportunity to share their voice, experience and depth of knowledge in ways that are critically important for our patients,” said Pari V. Pandharipande, MD, MPH, RSNA board liaison to the Government Relations Committee. “Equally, the insights gained will further enhance our community’s knowledge of best practices in the successful development and dissemination of cutting-edge imaging technologies at the population level. We are excited and grateful for this important collaborative opportunity.” 

RSNA joins other radiology-related organizations in the Network of Experts Program, including the American College of Radiology, American Society of Neuroradiology, American Society of Radiation Oncology, Radiation Research Society, Society of Breast Imaging and the Society of Interventional Radiology. 

To view the entire list of organizations participating in the program, click here. 

Hannah murhphy headshot

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She began covering the medical imaging industry for Innovate Healthcare in 2021.

Around the web

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.